These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29346837)

  • 1. A Phase 1, Randomized, Placebo- and Active-Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy Volunteers.
    Sahasrabudhe V; Saur D; Matschke K; Terra SG; Hickman A; Huyghe I; Shi H; Cutler DL
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):513-523. PubMed ID: 29346837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
    Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B
    Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
    Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A
    Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
    Kumagai Y; Hasunuma T; Sakai S; Ochiai H; Samukawa Y
    PLoS One; 2015; 10(10):e0139873. PubMed ID: 26444986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants.
    Krishnaswami S; Kudlacz E; Wang R; Chan G
    J Clin Pharmacol; 2011 Sep; 51(9):1256-63. PubMed ID: 21148043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.
    Mendell J; Kobayashi F; Shimizu T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):709-718. PubMed ID: 32255542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
    Zomorodi K; Chen D; Lee L; Swearingen D; Carter LP
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):404-413. PubMed ID: 32935460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
    Gottfridsson C; Carlson G; Lappalainen J; Sostek M
    Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Blinded, Placebo- and Positive-Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects.
    Fradette C; Rozova A; Stilman A; Tsang YC; Allison MJ; Tricta F
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):22-32. PubMed ID: 28394491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
    Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
    McCrea J; Mostoller K; Mahon C; Liu C; Liu F; Zajic S; Panebianco D; Chakravarthy M; Brandquist C; Gutierrez M; Stoch SA
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):861-870. PubMed ID: 31175709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
    Stier B; Fossler M; Liu F; Caltabiano S
    Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
    Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
    Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
    Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
    Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
    Lee RD; Nudurupati S; Marcinak J; Viswanathan P
    Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Eluxadoline Effect on Cardiac Repolarization.
    Bonifacio L; Hunt TL; McIntyre G; Dove LS; Covington PS
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):727-736. PubMed ID: 29659201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.